Key clinical point: Immune checkpoint inhibitors may be less effective if the patient is receiving corticosteroids at the time treatment is started.
Major finding: Corticosteroid use at the time of PD-1/PD-L1 blockade was associated with decreased progression-free survival (hazard ratio, 1.31; P = .03) and overall survival (HR, 1.66; P less than .001) in multivariate analysis.
Study details: Retrospective analysis of 640 patients treated with atezolizumab, durvalumab, nivolumab, or pembrolizumab at Memorial Sloan Kettering Cancer Center or Gustave Roussy Cancer Center.
Disclosures: The authors reported disclosures related to Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Janssen Pharmaceuticals, MedImmune, Merck, Mirati Therapeutics, Pfizer, Roche, Shattuck Labs, and Syndax, among others.
Arbour KC et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.79.0006.
This Week's Must Reads
No single genetic driver of metastases in ccRCC, Choueiri TK et al. Br J Cancer. 2018 May;118(9):1238-42.
Staging criteria for RCC with nodal involvement: Time to change?, Karam JA et al. Cancer. 2018 Oct 1. doi: 10.1002/cncr.31661.
RCC incidence rates stabilize while mortality rates drop, Saad AM et al. Clin Genitourin Cancer. 2018. doi: 10.1016/j.clgc.2018.10.002.
ADT and dementia in prostate cancer, Deka R et al. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4423.
Pazopanib appears safe in mRCC and renal failure, Masini C et al. Clin Genitourin Cancer. 2018 Oct 1. doi: 10.1016/j.clgc.2018.10.001.
Must Reads in Immuno-oncology
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9
Refractory esophagogastric cancer: Nivolumab plus ipilimumab ups response rate , Janjigian YY et al. J Clin Oncol. 2018 Aug 15. doi: 10.1200/JCO.2017.76.6212.
Baseline steroid use may decrease efficacy of checkpoint inhibitors, Arbour KC et al. J Clin Oncol. 2018 Aug 20. doi: 10.1200/JCO.2018.79.0006.
Nivolumab plus ipilimumab ups survival in melanoma patients with brain mets, Tawbi HA et al. N Engl J Med. 2018 Aug 23. doi: 10.1056/NEJMoa1805453
Safety, efficacy of third-line avelumab assessed for gastric cancer, Bang YJ et al. Ann Oncol. 2018 Jul 24. doi:10.1093/annonc/mdy264.